Matthew Paul Kowalsky
Known title: Chief Legal OfficerCIK: 0001705824
Associated companies
Transaction History
| ENTA | ▲ Buy | Grant | 1,318 | $0 | 2/12/2026 | View on chart |
| ENTA | ▲ Buy | Grant | 4,175 | $0 | 2/12/2026 | View on chart |
| ENTA | ▼ Sell | Tax Withholding | 1,902 | $27K | 2/12/2026 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
HC Wainwright Maintains $20 Target for Enanta
HC Wainwright reiterated its stance on Enanta Pharmaceuticals, keeping a price target of $20. This view aligns with the broader analyst consensus, where the average target across six analysts is $21.83. The stock is currently trading near its 52-week low, with recent technical signals indicating support at $13.25.
HC Wainwright Maintains $20 Target for Enanta. HC Wainwright reiterated its stance on Enanta Pharmaceuticals, keeping a price target of $20. This view aligns with the broader analyst consensus, where the average target across six analysts is $21.83. The stock is currently trading near its 52-week low, with recent technical signals indicating support at $13.25.